SCHEMBL2336082

SCHEMBL2336082

O=S(=O)(c1ccc(Cl)cc1)N(CCCc1ccccc1)[C@H]1CCC[C@@H]1O

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 9/20 0.59
PSEN2 P49810 9/20 0.59
APH1B Q8WW43 9/20 0.59
NCSTN Q92542 9/20 0.59
APH1A Q96BI3 9/20 0.59
PSENEN Q9NZ42 9/20 0.59
KCNA5 P22460 1/20 0.53
SLC18A3 Q16572 2/20 0.53
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 2/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
ADAMTS5 Q9UNA0 1/20 0.42
BACE1 P56817 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2336415 0.84 PSEN1 (0.62) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2332192 0.84 KCNA5 (0.73) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2338691 0.84 KCNA5 (0.73) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2333801 0.78 PSEN1 (0.55) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5516169 0.75 PSEN1 (0.94) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5520333 0.75 PSEN1 (0.94) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5517395 0.75 PSEN1 (0.86) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5520009 0.75 PSEN1 (0.86) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1877779 0.74 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5518099 0.74 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US claimed
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US disclosed
US-8193389-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2374792-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-10-12 EP disclosed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP disclosed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245573-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE PSEN1 1/4885PSEN2 2/4885APH1B 213/4885
US-20120270902-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE PSEN1 1/4885PSEN2 2/4885APH1B 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.